Hayato Kawachi

7PUBLICATIONS
47CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jul 10, 2025
Chemoimmunotherapy Outcomes and Prognostic Factors in Patients with Advanced, Low PD-L1-Expressing Non-Small Cell Lung Cancer.

Tae Hata, Tadaaki Yamada, Yasuhiro Goto

|Jun 19, 2025
Outcomes of chemotherapy with or without immunotherapy in older patients with non-small cell lung cancer and low PD-L1 expression.

Hayato Kawachi, Tae Hata, Tadaaki Yamada

|Nov 04, 2024
YAP Regulates HER3 Signaling-Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers.

Yuki Katayama, Tadaaki Yamada, Keiko Tanimura

|Oct 28, 2023
First-Line Chemoimmunotherapy versus Sequential Platinum-Based Chemotherapy Followed by Immunotherapy in Patients with Non-Small Cell Lung Cancer with ≤49% Programmed Death-Ligand 1 Expression: A Real-World Multicenter Retrospective Study.

Keiko Tanimura, Takayuki Takeda, Nobutaka Kataoka

|Oct 06, 2023
Effects of Combined Therapeutic Targeting of AXL and ATR on Pleural Mesothelioma Cells.

Soichi Hirai, Tadaaki Yamada, Yuki Katayama

|Jun 19, 2023
Rationale and design of phase II clinical trial of dual inhibition with ramucirumab and erlotinib in EGFR exon 19 deletion-positive treatment-naïve non-small cell lung cancer with high PD-L1 expression (SPIRAL-3D study).

Hayato Kawachi, Tadaaki Yamada, Akihiro Yoshimura

Pageof 2

Frequent Collaborators

5 joint publications

Tadaaki Yamada

4 joint publications

Koichi Takayama

3 joint publications

Keiko Tanimura

2 joint publications

Soichi Hirai